ALC vs TGTX
Alcon Inc vs TG Therapeutics, Inc. — AI-powered side-by-side comparison
VS
TGTX
TG Therapeutics, Inc.
60
Watch
| Metric | ALC | TGTX |
|---|
| AI Score |
68
|
60
|
| Price |
$75.39
|
$49.86
|
| P/E Ratio |
45.39×
|
16.39×
|
| ROE |
4.4%
|
69.0%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
54.9%
|
82.4%
|
| Debt / Equity |
0.24×
|
1.25×
|
| Dividend Yield |
0.5%
|
0.0%
|
| RSI (14) |
73.4
|
42.0
|
| Beta |
0.703
|
1.666
|
| Expected Upside |
+11.3%
|
—
|
AI Committee View
Current Innellis committee reasoning for ALC versus TGTX.
ALC leads by 8 points.
ALC scores 68/100 (Buy) versus TGTX at 60/100 (Watch).
ALC Committee View
75% agreement
4 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. The main limiting factor is rsi at 73 is in overbought territory. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- RSI at 73 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
TGTX Committee View
50% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 76.1% yoy -- genuine top-line momentum. Risk Analyst remains cautious — bollinger bandwidth of 22.5% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- ROE of 72.3% shows genuine earnings power backing the valuation — Value
- Revenue growing 76.1% YoY -- genuine top-line momentum — Growth
- EPS growing 633.7% YoY — Growth
Bear Case
- Price-to-book of 21.1x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
- Bollinger bandwidth of 22.5% signals elevated volatility — Risk